Eternal Energy Valuation
Is EE-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EE-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate EE-R's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate EE-R's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EE-R?
Other financial metrics that can be useful for relative valuation.
What is EE-R's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ฿611.60m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 100.6x |
Enterprise Value/EBITDA | -6.6x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does EE-R's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2x | ||
JSP JSP Pharmaceutical Manufacturing (Thailand) Public | 1.5x | n/a | ฿1.3b |
BLC Bangkok Lab And Cosmetic | 1.9x | n/a | ฿3.0b |
MEGA Mega Lifesciences | 3.8x | 11.1% | ฿35.7b |
CAN Cann Group | 0.5x | n/a | AU$27.1m |
EE-R Eternal Energy | 0.6x | n/a | ฿611.6m |
Price-To-Book vs Peers: EE-R is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (2x).
Price to Earnings Ratio vs Industry
How does EE-R's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Book vs Industry: EE-R is good value based on its Price-To-Book Ratio (0.6x) compared to the Asian Pharmaceuticals industry average (2.1x).
Price to Book Ratio vs Fair Ratio
What is EE-R's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 0.6x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate EE-R's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.